Randomised phase III study of copanlisib plus rituximab vs rituximab/placebo in relapsed indolent non-Hodgkin lymphoma

PC14586: The first orally bioavailable small molecule reactivator of Y220C mutant p53 in clinical development

First-line pembrolizumab plus chemotherapy for patients with advanced squamous NSCLC: 3-year follow-up from KEYNOTE-407

MERMAID-2: Phase 3 study of durvalumab in patients with resected stage MRD II-III NSCLC

Incorporating KRAS as a novel biomarker: Challenges and opportunities

Real world data and diagnostics in patients with NSCLC with EGFR exon 20 insertions

Challenges and solutions in PD-L1 testing in NSCLC

Current treatment standards for primary ovarian cancer

Evolving medical treatment in advanced/recurrent endometrial cancer

Nurse's perspective on PARP inhibitors and personalised medicine in prostate cancer

TALAPRO-1: phase II study of talazoparib in patients with DNA damage repair alterations and mCRPC

OncoAlert and ecancer weekly roundup for February 07 - 13, 2021